Evidence map›Paper›PMID 42694458›Full record

ArticleClinical case reports2026

Sintilimab Combined With Albumin-Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review.

Yufan Tang, Boquan Zhou, Bingbing Wen, Ke Yu, Jiajia Jia, Ying Sha, Jixiang Liu, Luyao Li, Ruifang Fan

Abstract read
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yufan TangDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.ORCID https://orcid.org/0009-0000-1826-0060
Boquan ZhouDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Bingbing WenDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Ke YuDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Jiajia JiaDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Ying ShaDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Jixiang LiuDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Luyao LiDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Ruifang FanDepartment of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.ORCID https://orcid.org/0009-0009-6869-4508

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD-1 inhibitor with albumin-bound paclitaxel and S-1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with favorable performance status and MDT-supported indications, as pathological complete remission appears to be attainable in this context.

Indexed as

albumin‐boundconversion therapygastric cancersintilimab

Identifiers

PMID42694458
PMCPMC13538948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.